{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:44:10Z","timestamp":1792701850545,"version":"4.5.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Amisulpride, a second-generation atypical antipsychotic drug, was first marketed in Europe in the 1990s. This study aimed to provide a reference for the clinical application of amisulpride. The effects of age, sex, or specific comedications on amisulpride concentrations in Chinese patients with schizophrenia in the real world were investigated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A retrospective study was conducted of data on amisulpride based on the therapeutic drug monitoring service database at the Zigong Affiliated Hospital of Southwest Medical University.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Based on the inclusion criteria, 195 plasma samples from 173 patients (67.05% female and 32.95% male patients) were included for in-depth analysis. The median daily dose of amisulpride was 400 mg\/d, median plasma concentration was 457.50 ng\/mL, and median concentration\/dose (C\/D) ratio was 1.04 ng\/mL\/mg\/d. The daily dose of amisulpride positively correlated with measured steady-state plasma concentrations. A significant difference was observed in the subgroup analysis of the combination with valproic acid, zopiclone, or aripiprazole on plasma concentrations. Combining amisulpride with these drugs increased the C\/D ratios by 0.56-, 2.31-, and 0.77-fold, respectively. After adjusting for age, the median C\/D ratio was found to be significantly different between female and male patients. However, no significant differences in daily dose, plasma concentration, and C\/D ratio were noted with respect to sex and age of the patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Sex differences were inferred for the first time in this study, with differential effects on daily dose, steady-state plasma concentration, and C\/D ratio associated with the population. In the included study samples, blood concentrations were distributed in the range of 223.25\u2013823.55 ng\/mL, which perhaps needs to be evaluated in line with the reference range of ammonia\u2013sulfur ratios in the Chinese population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001089","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T22:00:07Z","timestamp":1677794407000},"page":"676-682","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Age, Sex, and Comedication Effects on the Steady-State Plasma Concentrations of Amisulpride in Chinese Patients with Schizophrenia"],"prefix":"10.1097","volume":"45","author":[{"given":"Shuo","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Jianyang People's Hospital, Chengdu; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HaiYan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jianyang Chinese Medicine Hospital, Chengdu, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao Feng","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jianyang People's Hospital, Chengdu; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Zigong Affiliated Hospital of Southwest Medical University;"},{"name":"Zigong Psychiatric Research Center, Zigong;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"977","DOI":"10.12740\/PP\/OnlineFirst\/109129","article-title":"Amisulpride-is it as all other medicines or is it different? An update","volume":"54","author":"Hadry\u015b","year":"2020","journal-title":"Psychiatr Pol."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s12888-018-1867-8","article-title":"Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis","volume":"18","author":"Men","year":"2018","journal-title":"BMC Psychiatry"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.euroneuro.2003.09.001","article-title":"Plasma amisulpride levels in schizophrenia or schizoaffective disorder","volume":"14","author":"Bergemann","year":"2004","journal-title":"Eur Neuropsychopharmacol."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.2165\/00003495-200161140-00014","article-title":"Amisulpride: a review of its use in the management of schizophrenia","volume":"61","author":"Curran","year":"2001","journal-title":"Drugs"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)36395-5","article-title":"Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 receptor antagonist with both presynaptic and limbic selectivity","volume":"280","author":"Schoemaker","year":"1997","journal-title":"J Pharmacol Exp Ther."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/bcp.14246","article-title":"A systematic review and combined meta-analysis of concentration of oral amisulpride","volume":"86","author":"Li","year":"2020","journal-title":"Br J Clin Pharmacol."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"102694","DOI":"10.1016\/j.ajp.2021.102694","article-title":"Study on the relationship among dose, concentration and clinical response in Chinese schizophrenic patients treated with Amisulpride","volume":"62","author":"Sun","year":"2021","journal-title":"Asian J Psychiatry"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-3565(24)36394-3","article-title":"Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2\/D3 dopamine receptor antagonist activity and limbic selectivity","volume":"280","author":"Perrault","year":"1997","journal-title":"J Pharmacol Exp Ther."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2165\/00023210-200418130-00007","article-title":"Amisulpride: a review of its use in the management of schizophrenia","volume":"18","author":"McKeage","year":"2004","journal-title":"CNS Drugs"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"The Lancet"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/HRP.0b013e31827fd915","article-title":"The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia","volume":"21","author":"Osser","year":"2013","journal-title":"Harv Rev Psychiatry"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00228-021-03114-z","article-title":"Impact of age and gender on paliperidone exposure in patients after administration of long-acting injectable formulations-an observational study using blood samples from 1223 patients","volume":"77","author":"Tveito","year":"2021","journal-title":"Eur J Clin Pharmacol."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.yic.0000188213.46667.f1","article-title":"Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations","volume":"21","author":"Aichhorn","year":"2006","journal-title":"Int Clin Psychopharmacol."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/acps.12794","article-title":"Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine","volume":"136","author":"Castberg","year":"2017","journal-title":"Acta Psychiatr Scand."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/14656566.2020.1714029","article-title":"An overview of intravenous amisulpride as a new therapeutic option for the prophylaxis and treatment of postoperative nausea and vomiting","volume":"21","author":"Smyla","year":"2020","journal-title":"Expert Opin Pharmacother."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1600-0447.2009.01429.x","article-title":"Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring","volume":"120","author":"Sparshatt","year":"2009","journal-title":"Acta Psychiatrica Scand."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.2147\/DDDT.S327506","article-title":"Modeling and simulation for individualized therapy of amisulpride in Chinese patients with schizophrenia: focus on interindividual variability, therapeutic reference range and the laboratory alert level","volume":"15","author":"Huang","year":"2021","journal-title":"Drug Des Develop Ther."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1208\/s12248-014-9649-9","article-title":"The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family","volume":"16","author":"Dos Santos Pereira","year":"2014","journal-title":"AAPS J."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1208\/s12248-013-9465-7","article-title":"Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney","volume":"15","author":"Motohashi","year":"2013","journal-title":"AAPS J."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/0269881108089806","article-title":"Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder","volume":"23","author":"M\u00fcller","year":"2009","journal-title":"J Psychopharmacol."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-2006-931540","article-title":"Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study","volume":"39","author":"M\u00fcller","year":"2006","journal-title":"Pharmacopsychiatry"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/FTD.0b013e3181956726","article-title":"Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole","volume":"31","author":"Waade","year":"2009","journal-title":"Ther Drug Monit."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.neurol.2017.02.004","article-title":"Influence of age and co-medication on the steady-state pharmacokinetics of valproic acid in Tunisian patients with epilepsy","volume":"173","author":"Ben Mahmoud","year":"2017","journal-title":"Revue Neurologique"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1124\/dmd.106.014456","article-title":"Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways","volume":"35","author":"Cerveny","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1002\/jps.23593","article-title":"Studies on pharmacokinetic mechanism of phenytoin resistance in refractory epilepsy","volume":"102","author":"Lai","year":"2013","journal-title":"J Pharm Sci."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1211\/0022357043969","article-title":"Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates","volume":"56","author":"El Ela","year":"2004","journal-title":"J Pharm Pharmacol."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00702-005-0367-4","article-title":"Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp)","volume":"113","author":"Schmitt","year":"2006","journal-title":"J Neural Transm."},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2217\/pgs.11.55","article-title":"Relationship between P-glycoprotein and second-generation antipsychotics","volume":"12","author":"Moons","year":"2011","journal-title":"Pharmacogenomics"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/FTD.0b013e3182708ec5.","article-title":"Therapeutic drug monitoring of common antipsychotics","volume":"34","author":"Patteet","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/JCP.0b013e31814f4dbb","article-title":"Increase in plasma concentration of amisulpride after addition of concomitant lithium","volume":"27","author":"Bergemann","year":"2007","journal-title":"J Clin Psychopharmacol."},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"e3928","DOI":"10.1002\/bmc.3928","article-title":"Development of a UPLC-MS\/MS method for routine therapeutic drug monitoring of aripiprazole, amisulpride, olanzapine, paliperidone and ziprasidone with a discussion of their therapeutic reference ranges for Chinese patients","volume":"31","author":"Wang","year":"2017","journal-title":"Biomed Chromatogr."},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/FTD.0000000000000582","article-title":"Concentration-effect relationships of psychoactive drugs and the problem to calculate therapeutic reference ranges","volume":"41","author":"Hiemke","year":"2019","journal-title":"Ther Drug Monit."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:15:04Z","timestamp":1748970904000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001089","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"assertion":[{"value":"2022-11-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}